Press Releases – Biome Diagnostics | BiomeDx

Austrian MedTech Biome Diagnostics goes NASDAQ

Catia Pacifico — Tue, 27 Jun 2023 08:44:03 +0000

Biome Diagnostics receives multiple awards for excellence, and advertising space at NASDAQ Tower in Times Square, New York Vienna, June 26, 2023 – Biome Diagnostics, a leading Austrian company in the field of medical microbiome diagnostics, has won several awards for outstanding performance at many internationally renowned events. The awards highlight the company’s commitment and innovation…

Source

BiomeDx and SanusX announce strategic partnership

Catia Pacifico — Mon, 26 Jun 2023 08:16:16 +0000

SanusX acquires a stake of around 20% in Austrian MedTech company Biome Diagnostics GmbH Vienna, June 26, 2023 – Biome Diagnostics GmbH (BiomeDx), an Austrian MedTech company that specializes in medical diagnostics and applications related to the intestinal microbiome forged a strategic partnership for growth in cutting-edge diagnostic procedures with SanusX. Founded in 2018…

Source

BiomeDx Wins Startup Audience Award

Nikolaus Gasche — Tue, 08 Nov 2022 15:20:52 +0000

Vienna, November 7, 2022 – Biome Diagnostics reaches second place in the Startup competition at the Web Summit in Lisbon and wins the public vote with 56 percent of the votes. The Web Summit is one of the most important and largest tech conferences in Europe. Around 2,000 young companies presented their technologies and business models in front of international investors. The approach and vision…

Source

Intestinal microbiome as cancer hope: new predictive test makes life easier for patients

Nikolaus Gasche — Mon, 18 Jul 2022 15:40:00 +0000

VIENNA, July 2022: Vienna-based Biome Diagnostics launches the first and only gut microbiome-based predictive test to date, BiomeOne®. The test analyzes and evaluates the response to immunotherapy (ICI) against cancer and the likelihood of side effects. Clinical studies have confirmed its efficacy. BiomeOne® is certified and approved as a medical device (CE-IVD).

Source

Biome Diagnostics identifies tumor-agnostic biomarker for cancer immunotherapy in a new meta-analysis of microbiome studies

Nikolaus Gasche — Tue, 02 Nov 2021 10:08:30 +0000

VIENNA, November 2021: The Austrian MedTech company BiomeDx has dedicated its efforts to advance precision medicine and is pioneering the development of a biomarker for cancer immunotherapy based on the intestinal microbiome. In a recent poster BiomeDx presented a study-based meta-analysis of advanced non-small cell lung cancer (NSCLC) and melanoma patients that supports the potential of the human…

Source

Biome Diagnostics has received six-digit funding from the Austrian Research Promotion Agency (FFG)

Barbara Sladek — Fri, 21 May 2021 12:25:15 +0000

VIENNA, April 2021: Biome Diagnostics GmbH is a global leader in microbiome diagnostics and specializes in the analysis and interpretation of the human intestinal microbiome. Currently, the Austrian company puts all efforts in the development of a diagnostic analysis for response/non-response to immune-checkpoint inhibitors (ICIs) based on the signature of the intestinal microbiome of individual…

Source

Bioinformatics scale-up Biome Diagnostics launches Austria-wide, multi-centre cancer study “BiomeOne”

Nikolaus Gasche — Mon, 22 Mar 2021 09:03:49 +0000

VIENNA, March 2021: The Austrian company is a global leader in microbiome diagnostics and specialises in the analysis and subsequent interpretation of the human intestinal microbiome using in-house software algorithms. The intestinal bacteria play an essential role in shaping the body’s immune response. The influence of the microbiome on the response to modern cancer immunotherapies (immune…

Source

myBioma becomes Biome Diagnostics

Nikolaus Gasche — Sat, 20 Feb 2021 09:03:50 +0000

VIENNA, February 2021: The Austrian company developed a lifestyle product to analyse the gut microbiome for end-consumers. Since the product launch across Europe in 2019, the company has gathered thousands of data points. In January 2021, the company had its successful surveillance audit for its certification according ISO 13485 (manufacturing of medical products) and ISO 9001 (quality management).

Source

Successful completion of the Data Science Bootcamp of the Austrian Research Promotion Agency (FFG)

Nikolaus Gasche — Mon, 25 Jan 2021 17:41:00 +0000

VIENNA, January 2021: From April to December 2020, myBioma‘s bioinformatician Christian Jansen had the chance to participate in the FFG Data Science Bootcamp at St. Pölten University of Applied Sciences. The bootcamp covered various topics ranging from planning and collecting study data, data preparation and modelling to the final evaluation and presentation of the results. Specifically…

Source